

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 30, 2023**

**Predictive Oncology Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**001-36790**

(Commission File Number)

**33-1007393**

(I.R.S. Employer Identification No.)

**2915 Commers Drive, Suite 900**

**Eagan, Minnesota 55121**

(Address of Principal Executive Offices) (Zip Code)

**(651) 389-4800**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.01 par value	POAI	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 30, 2023, the Board of Directors of Predictive Oncology Inc. (the “Company”) appointed Pamela Bush, Ph.D., MBA, age 49, as Chief Business Officer.

Dr. Bush brings more than twenty years of experience in venture creation, finance and business development in the life sciences industry. Dr. Bush has served as the Company’s Senior Vice President of Strategic Sales and Business Development since December 2021. Before joining the Company, Dr. Bush worked at Eli Lilly & Company from September 2009 until June 2016, and again from January 2019 until November 2021. While at Eli Lilly & Company, Dr. Bush served in various roles including Corporate Business Development, Finance and Patient Services. She served as the Director of Immunology at Lilly Patient Services, Eli Lilly & Company, primarily focusing on managing vendor performance and relationships, as well as negotiating contracts and finding workflow efficiencies. Before that, Dr. Bush served as Director of Corporate Business Development at Eli Lilly & Company. Between June 2016 and January 2019, Dr. Bush founded BluGene Consulting, a consultancy supporting emerging life science companies that focused on new client acquisition and private investor fundraising, where she served as managing partner. Pamela Bush earned her Ph.D. in Molecular Biology from Carnegie Mellon University (CMU) and MBA from CMU’s Tepper School of Business.

A press release announcing the foregoing matters is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit No.**      **Description**

<a href="#">99.1</a>	<a href="#">Press Release dated February 3, 2023</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)



**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Predictive Oncology Inc.**

Date: February 3, 2023

By: /s/ Bob Myers  
Bob Myers  
Chief Financial Officer

**Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer**

EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology.

As a key member of the executive team, Dr. Bush will spearhead the company's strategic, operational and financial planning initiatives for both existing customers and emerging new markets. She will work closely with the company's senior management in leveraging and expanding its portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company's biopharma partners.

"In terms of scientific intelligence, industry insight and understanding the business of biopharma, Pamela is at the top of her game," said Raymond F. Vennare, Chief Executive Officer and Chairman of the Board for Predictive Oncology. "She honed these skills over twenty years of experience analyzing emerging markets in life sciences, capital formation for early-stage companies and, most recently, leading business development efforts for Eli Lilly & Company."

Dr. Bush previously served as Senior Vice President of Strategic Sales and Business Development at Predictive Oncology. In that role, she was instrumental in guiding the company's strategic direction, expanding its product offerings and launching commercialization efforts for the company's flagship technology platform.

"We have the power to change the way drugs are discovered and developed. I'm looking forward to further impacting the future of oncology drug discovery and driving adoption of solutions that can move compounds into clinical trials faster and with higher confidence," noted Dr. Bush. "These efforts collectively benefit our partners, investors and other stakeholders, but most importantly, cancer patients waiting for therapies to be developed."

Dr. Bush brings more than twenty years of experience in venture creation, finance and business development in the life sciences industry. Before joining Predictive Oncology in December of 2021, Dr. Bush worked at Eli Lilly & Company in various roles including Corporate Business Development, Finance and Patient Services. She served as the Director of Immunology at Lilly Patient Services, Eli Lilly & Company, primarily focusing on managing vendor performance and relationships, as well as negotiating contracts and finding workflow efficiencies. Before that, Dr. Bush served as Director of Corporate Business Development at Eli Lilly & Company. She was also the founder and managing partner of BluGene Consulting, a consultancy supporting emerging life science companies that focused on new client acquisition and private investor fundraising. Throughout her career, Dr. Bush has supported the creation and growth of more than 100 life sciences start-ups.

Dr. Bush currently serves on the Board of Directors for Cvergenx, is a frequent presenter on oncology drug discovery and serves in various volunteering and mentorship roles. She earned her Ph.D. in Biology from Carnegie Mellon University (CMU) and MBA from CMU's Tepper School of Business.



Predictive Oncology Appoints  
Pamela Bush, Ph.D., MBA,  
as Chief Business Officer

**About Predictive Oncology**

As a science-driven company on the leading edge of oncology drug discovery, Predictive Oncology (NASDAQ: POAI) offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world's largest privately held biobank of over 150K tumor samples. Predictive Oncology's solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise.

**Public Relations Contact:**

Predictive Oncology  
Theresa Ferguson  
(630) 566-2003  
tferguson@predictive-oncology.com

**Investor Relations Contact:**

Landon Capital  
Keith Pinder  
(404) 995-6671  
kpinder@landoncapital.net

**Forward-Looking Statements:**

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "would," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading "Risk Factors" in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.